DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: NVB
Drug: DDP
Drug: Endostar

First Posted Date: 2016-01-28

Last Posted Date: 2016-01-28

Lead Sponsor: Fudan University

Target Recruit Count: 76

Registration Number: NCT02665702

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Irinotecan as 3rd Line Therapy in Gastric Cancer

Phase 2

Conditions: Stomach Neoplasms

Interventions: Drug: Irinotecan

First Posted Date: 2016-01-26

Last Posted Date: 2016-01-26

Lead Sponsor: Fudan University

Target Recruit Count: 93

Registration Number: NCT02662959

Locations: 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC

Phase 2

Completed

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Radiation: thoracic radiation
Drug: Huachansu

First Posted Date: 2016-01-06

Last Posted Date: 2024-11-26

Lead Sponsor: Fudan University

Target Recruit Count: 126

Registration Number: NCT02647125

Locations: 🇨🇳
Fudan Universtiy Shanghai Cancer Center, Shanghai, Shanghai, China

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Phase 2

Active, not recruiting

Conditions: Triple Negative Breast Cancer
Breast Cancer

Interventions: Drug: docetaxel
Drug: doxorubicin or epirubicin
Drug: cyclophosphamide
Drug: gemcitabine
Drug: cisplatin

First Posted Date: 2015-12-30

Last Posted Date: 2024-01-25

Lead Sponsor: Fudan University

Target Recruit Count: 503

Registration Number: NCT02641847

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer

Phase 2

Conditions: Carcinoma, Pancreatic

Interventions: Procedure: Intravenous chemotherapy
Procedure: Transcatheter arterial infusion
Drug: Gemcitabine
Drug: Oxaliplatin

First Posted Date: 2015-12-21

Last Posted Date: 2020-03-05

Lead Sponsor: Fudan University

Target Recruit Count: 168

Registration Number: NCT02635971

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors

Not Applicable

Completed

Conditions: Thymoma and Thymic Carcinoma

Interventions: Radiation: concurrent chemoradiation

First Posted Date: 2015-12-21

Last Posted Date: 2020-02-07

Lead Sponsor: Fudan University

Target Recruit Count: 56

Registration Number: NCT02636556

Locations: 🇨🇳
Kailiang Wu, Shanghai, Shanghai, China

Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis

Phase 2

Conditions: Carcinoma, Pancreatic

Interventions: Procedure: radiofrequency ablation
Drug: S-1

First Posted Date: 2015-12-18

Last Posted Date: 2015-12-18

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT02634502

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection

Not Applicable

Recruiting

Conditions: Thymoma

Interventions: Radiation: adjuvant radiotherapy

First Posted Date: 2015-12-17

Last Posted Date: 2023-12-08

Lead Sponsor: Fudan University

Target Recruit Count: 238

Registration Number: NCT02633553

Locations: 🇨🇳
Kailiang Wu, Shanghai, Shanghai, China

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

Phase 3

Recruiting

Conditions: Thymoma and Thymic Carcinoma

Interventions: Drug: Cisplatin
Drug: Etoposide
Radiation: radiotherapy

First Posted Date: 2015-12-17

Last Posted Date: 2023-12-05

Lead Sponsor: Fudan University

Target Recruit Count: 1

Registration Number: NCT02633514

Locations: 🇨🇳
Kailiang Wu, Shanghai, Shanghai, China

Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation

Phase 4

Conditions: Carcinoma, Hepatocellular
Neoplastic Cells, Circulating

Interventions: Procedure: TACE
Drug: Epirubicin
Drug: lipiodol

First Posted Date: 2015-12-16

Last Posted Date: 2015-12-22

Lead Sponsor: Fudan University

Target Recruit Count: 256

Registration Number: NCT02631499

Locations: 🇨🇳
Nantong Tumor Hospital, Nantong, Jiangsu, China
🇨🇳
The First Affiliated Hospital of Soochow University, Soochow, Jiangsu, China
🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy